Cargando…
Clinical Efficacy and Safety Evaluation of Ceftazidime-Avibactam in the Treatment of Klebsiella pneumoniae Infection: A Retrospective Analysis from a Hospital in China
BACKGROUND: Ceftazidime-avibactam (CAZ-AVI) is a new cephalosporin/β-lactamase inhibitor combination that received clinical approval in China in 2019. This study aims to investigate the efficacy and safety of CAZ-AVI in the treatment of Klebsiella pneumoniae (KP) infection in a hospital, and differe...
Autores principales: | Xu, Jia, Luo, Chengjia, Huang, Liang, Xiao, Xi, Liu, Ling, Yang, Zhiling |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10656859/ https://www.ncbi.nlm.nih.gov/pubmed/38023408 http://dx.doi.org/10.2147/IDR.S435882 |
Ejemplares similares
-
Ceftazidime/Avibactam Resistance in Carbapenemase-Producing Klebsiella pneumoniae
por: Cui, Qiaozhen, et al.
Publicado: (2023) -
Reduced Ceftazidime-Avibactam Susceptibility in KPC-Producing Klebsiella pneumoniae From Patients Without Ceftazidime-Avibactam Use History – A Multicenter Study in China
por: Cui, Xiaoyan, et al.
Publicado: (2020) -
In vitro Optimization of Ceftazidime/Avibactam for KPC-Producing Klebsiella pneumoniae
por: Huang, Yanqin, et al.
Publicado: (2021) -
Emergence of Ceftazidime- and Avibactam-Resistant Klebsiella pneumoniae Carbapenemase-Producing Pseudomonas aeruginosa in China
por: Zhu, Yiwei, et al.
Publicado: (2021) -
Ceftazidime-Avibactam for Hospital Acquired Pneumonia Due to Extended Drug-Resistant Klebsiella pneumoniae
por: Rup, Amit Ranjan, et al.
Publicado: (2020)